IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CAVALIERI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.429
NA - Nord America 5.944
AS - Asia 5.600
SA - Sud America 523
AF - Africa 147
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 5
Totale 18.689
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.769
DE - Germania 3.197
CN - Cina 1.715
SG - Singapore 1.449
IT - Italia 1.049
HK - Hong Kong 507
BD - Bangladesh 418
BR - Brasile 404
GB - Regno Unito 396
RU - Federazione Russa 371
VN - Vietnam 327
JP - Giappone 298
SE - Svezia 295
IN - India 288
FR - Francia 275
ES - Italia 153
NL - Olanda 153
ID - Indonesia 119
CA - Canada 112
FI - Finlandia 109
IE - Irlanda 107
TW - Taiwan 107
KR - Corea 71
DK - Danimarca 53
CI - Costa d'Avorio 47
TR - Turchia 47
MA - Marocco 42
AR - Argentina 41
AT - Austria 41
PH - Filippine 40
AU - Australia 39
CH - Svizzera 37
PL - Polonia 37
MX - Messico 33
UA - Ucraina 27
TH - Thailandia 26
IQ - Iraq 25
EC - Ecuador 20
BE - Belgio 19
MY - Malesia 19
CO - Colombia 17
IR - Iran 17
UZ - Uzbekistan 17
ZA - Sudafrica 17
NO - Norvegia 15
PK - Pakistan 15
SA - Arabia Saudita 14
VE - Venezuela 14
PT - Portogallo 13
RO - Romania 13
GR - Grecia 12
IL - Israele 12
RS - Serbia 11
JO - Giordania 10
PE - Perù 10
KE - Kenya 8
AZ - Azerbaigian 7
CL - Cile 7
CZ - Repubblica Ceca 7
JM - Giamaica 7
KZ - Kazakistan 7
NP - Nepal 7
OM - Oman 7
PY - Paraguay 7
SC - Seychelles 7
AE - Emirati Arabi Uniti 6
CR - Costa Rica 6
EG - Egitto 6
HU - Ungheria 6
AL - Albania 5
PA - Panama 5
TN - Tunisia 5
AM - Armenia 4
HR - Croazia 4
LB - Libano 4
BY - Bielorussia 3
CY - Cipro 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
LU - Lussemburgo 3
NG - Nigeria 3
AD - Andorra 2
AP - ???statistics.table.value.countryCode.AP??? 2
BG - Bulgaria 2
BO - Bolivia 2
DZ - Algeria 2
IS - Islanda 2
LK - Sri Lanka 2
LT - Lituania 2
MD - Moldavia 2
MO - Macao, regione amministrativa speciale della Cina 2
PS - Palestinian Territory 2
SI - Slovenia 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CM - Camerun 1
Totale 18.661
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 2.910
Dallas 1.378
Singapore 766
Ashburn 614
Hong Kong 449
San Jose 370
Chandler 273
Milan 268
Southend 260
Beijing 259
Santa Clara 245
Fairfield 203
Hefei 177
Council Bluffs 159
Los Angeles 138
Tokyo 131
New York 119
Redwood City 117
Ho Chi Minh City 115
Princeton 111
Dublin 104
Jakarta 99
Seattle 94
Lauterbourg 92
Bengaluru 87
Hanoi 84
Shanghai 83
Wilmington 81
Woodbridge 79
Buffalo 78
Houston 76
Helsinki 75
Rome 72
Guangzhou 68
Moscow 67
Ann Arbor 63
Boardman 57
Chicago 56
Munich 54
Seoul 52
Cambridge 51
Taipei 51
Abidjan 47
São Paulo 46
Nanjing 45
Dearborn 42
London 42
Naples 41
Des Moines 39
Berlin 36
Grafing 35
Nuremberg 35
Cangzhou 31
Madrid 31
Hyderabad 29
Ottawa 26
Shenyang 26
Bologna 25
Istanbul 25
Hanover 24
Paris 24
Tianjin 24
Toronto 24
Turin 24
Atlanta 22
Hangzhou 21
Jinan 21
Shenzhen 21
Bangkok 20
Phoenix 20
Lappeenranta 19
Washington 19
Rabat 18
Wuhan 18
Columbus 17
Amsterdam 16
Changsha 16
Chennai 16
Florence 16
Nanchang 16
Vienna 16
Warsaw 16
Da Nang 14
Fuzhou 14
Montreal 14
Rio de Janeiro 14
Tashkent 14
Zhengzhou 14
Zurich 14
Campinas 13
Chengdu 13
Denver 13
Dong Ket 13
Mumbai 13
Pavia 13
San Diego 13
San Francisco 13
Silver Spring 13
Turku 13
Haiphong 12
Totale 11.974
Salva come PNG Salva come JPEG
Nome #
Lenvatinib-induced renal failure : two first-time case reports and review of literature 1.152
Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis 635
Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study 487
Clinical implications for pro-GRP in small cell lung cancer. A single center experience 439
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial 415
Ferroptosis-Related Gene Signatures: Prognostic Role in HPV-Positive Oropharyngeal Squamous Cell Carcinoma 409
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? 345
A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol 330
Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients 313
Interplay between MRI radiomics and immune gene expression signatures in oral squamous cell carcinoma 297
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC) 274
Modelling radiation‐induced salivary dysfunction during IMRT and chemotherapy for nasopharyngeal cancer patients 261
Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer 244
Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract 238
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents 236
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients 234
Baseline mri-radiomics can predict overall survival in non-endemic ebv-related nasopharyngeal carcinoma patients 231
Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report 225
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer 218
Locally advanced epithelial sinonasal tumors: The impact of multimodal approach 213
HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients 211
The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers 207
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/ metastatic head and neck squamous cell carcinoma treated with nivolumab 207
Identification of potentially druggable molecular alterations in skin adnexal malignancies 205
Radiation-Induced Oropharyngeal Squamous Cell Carcinoma: Case Report and Review of the Literature 204
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer 203
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment 199
An old but still unanswered question in recurrent or metastatic salivary duct carcinoma 195
Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities 194
Quality of life in head and neck cancer survivors: the Big Data for Quality of Life study 190
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: case series and large-scale pharmacovigilance analysis 190
Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies 187
Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study 187
A randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy of Aqualief™ mucoadhesive tablets in head and neck cancer patients who developed radiation-induced xerostomia 184
Management of patients with skin adnexal carcinomas 183
Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers 180
Claudin-1 in Head and Neck Squamous Cell Carcinoma 178
Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era 178
HeNeCOn: An ontology for integrative research in Head and Neck cancer 175
Biological Rationale and Clinical Evidence of Carbon Ion Radiation Therapy for Adenoid Cystic Carcinoma: A Narrative Review 175
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic 174
Management of loco-regionally advanced squamous laryngeal cancer in elderly patients 173
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients 172
Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project 171
Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirus-Positive Oropharyngeal Carcinoma 171
A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinoma 171
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial 165
NUT carcinoma of the submandibular gland: A case report 164
Immuno-oncology in head and neck squamous cell cancers : News from clinical trials, emerging predictive factors and unmet needs 161
The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies 159
Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case 158
Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial 153
Mining of self-organizing map gene-expression portraits reveals prognostic stratification of HPV-positive head and neck squamous cell carcinoma 152
Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting : the INT Milan experience 151
Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience 149
Bleeding complications in patients with squamous cell carcinoma of the head and neck 147
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure 145
Hedgehog inhibitors beyond clinical complete response in basal cell carcinoma: should I stop or should I go? 144
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma 144
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life 144
Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients 144
Prognostic radiomic signature for head and neck cancer: Development and validation on a multi-centric MRI dataset 143
Targeted-gene sequencing to catch triple negative breast cancer heterogeneity before and after neoadjuvant chemotherapy 142
AKR1C3 is a biomarker and druggable target for oropharyngeal tumors 141
Uncommon somatic mutations in metastatic NUT midline carcinoma 139
Particle beam therapy tolerance and outcome on patients with autoimmune diseases : A single institution matched case–control study 139
Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy 136
Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands 135
A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images 135
Current status and perspectives in immunotherapy for metastatic melanoma 134
Oral cancer in young adults: incidence, risk factors, prognosis, and molecular biomarkers 133
MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures 130
Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review 129
MRI radiomics in head and neck cancer from reproducibility to combined approaches 128
Indirect comparison ofTPF and GP induction chemotherapy regimens in nasopharyngeal carcinoma: a data-driven reassessment before the transition to induction chemoimmunotherapy 128
Quality Assessment in Supportive Care in Head and Neck Cancer 128
Editorial: Diagnosis, epidemiology and treatment of salivary gland carcinomas 126
Induction chemotherapy is the best timekeeper in nasopharyngeal carcinoma 125
Local therapies for liver metastases of rare head and neck cancers: A monoinstitutional case series 121
Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib 117
Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers 116
Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting 115
Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification 114
Fatigue, a major still underestimated issue 113
Integrating population data in a computerized Decision Support System for Head and Neck Cancer 110
Smartphone-Based Strategy for Quality-of-Life Monitoring in Head and Neck Cancer Survivors 109
Rare thyroid malignancies in Europe : Data from the information network on rare cancers in Europe (RARECAREnet) 109
Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials 108
Which future for de-intensified treatments in HPV-related oropharyngeal carcinoma? 105
Methodology and technology for the development of a prognostic MRI-based radiomic model for the outcome of head and neck cancer patients 102
Unusual skin carcinomas induced by BRAF inhibitor for metastatic melanoma: A case report 102
Systemic anticancer therapy during end of life in head and neck squamous cell carcinoma patients. A retrospective single center study 101
An Ontology for Quality of Life Modeling in Head and Neck Cancer 100
HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19 97
Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma 94
Prognostic gene expression signatures for HPV-negative head and neck squamous cell carcinoma 87
Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report 87
Lenvatinib in advanced thyroid, salivary gland, endometrial, and hepatocellular carcinomas: a real-world study on treatment duration and toxicity management 81
Erratum: Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy (PLoS ONE (2020) 15:5 (e0232639) DOI: 10.1371/journal.pone.0232639) 78
Developing a trial design to establish BNCT as clinical application: insight for the national italian center for oncological hadrontherapy (CNAO) 75
Totale 18.852
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.135
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.135
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202193 0 0 0 0 0 0 0 0 0 0 0 93
2021/20221.086 75 62 55 51 129 75 56 116 111 97 69 190
2022/20231.207 161 104 123 106 98 201 39 63 109 69 95 39
2023/20242.828 51 84 75 58 193 103 382 295 230 379 493 485
2024/20253.785 438 500 389 390 182 179 158 249 146 272 296 586
2025/20268.033 599 482 1.810 557 551 363 739 361 739 460 857 515
Totale 19.238